文献速递骨肿瘤

化疗诱导坏死对高危局限性骨肉瘤生存的影响

Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
PubMed 文献 · Bone Joint J · 2020-01-01

该研究纳入1997至2016年间232例≤40岁、初诊无临床可检测转移并接受术前MAP化疗及手术的高级别局限性骨肉瘤患者。多因素Cox模型显示化疗诱导坏死与无事件生存(EFS)和总生存(OS)显著相关,坏死与5年EFS、OS呈正相关;EFS和OS的最佳截断值分别为85%和72%,低于常用的90%。

要点

  • 化疗诱导坏死与EFS、OS显著相关,5年OS为74%(95%CI 67至79)。
  • 坏死与5年EFS正相关(r=0.91),与5年OS正相关(r=0.85)。
  • EFS与OS最佳截断值分别为85%和72%,低于常用90%。

核心结论

  • 切除标本中化疗诱导坏死与高级别局限性骨肉瘤患者MAP化疗后的EFS和OS呈正相关。
  • 本分析中EFS与OS的最佳截断值低于常用的90%,提示需通过更大规模国际协作研究重新评估最佳截断值。

研究设计与样本

  • 回顾性纳入1997至2016年625例≤40岁原发高级别骨肉瘤患者中的232例,均初诊无临床可检测转移并接受术前高剂量甲氨蝶呤、阿霉素和顺铂(MAP)化疗及手术。
  • 采用Cox模型和Pearson相关系数评估坏死与EFS、OS的关联,并应用时间依赖ROC分析确定最佳截断值。

主要发现

  • 5年OS为74%(95%CI 67至79)。
  • 化疗诱导坏死中位数为85%(IQR 50%至97%)。
  • 多因素Cox模型中坏死与EFS显著相关(HR=0.99,95%CI 0.98至0.99;p<0.001),与OS显著相关(HR=0.98,95%CI 0.97至0.99;p<0.001)。
  • 坏死与5年EFS正相关(r=0.91;p<0.001),与5年OS正相关(r=0.85;p<0.001)。

关键数值与推荐

  • 5年EFS的最佳化疗诱导坏死截断值为85%。
  • 5年OS的最佳化疗诱导坏死截断值为72%。

临床怎么用

  • 对接受术前MAP化疗的高级别局限性骨肉瘤患者,可依据切除标本坏死程度评估EFS和OS风险。
  • 本研究中EFS与OS最佳截断值低于常用90%,提示临床解读坏死阈值时需谨慎并期待更大规模研究验证。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To assess the correlation between the histological response to preoperative chemotherapy and event-free survival (EFS) or overall survival (OS) in patients with high-grade localized osteosarcoma. METHODS: Out of 625 patients aged ≤ 40 years treated for primary high-grade osteosarcoma between 1997 and 2016, 232 patients without clinically detectable metastases at the time of diagnosis and treated with preoperative high-dose methotrexate, adriamycin and cisplatin (MAP) chemotherapy and surgery were included. Associations of chemotherapy-induced necrosis in the resected specimen and EFS or OS were assessed using Cox model and the Pearson's correlation coefficients (r). Time-dependent receiver operating characteristic analysis was applied to determine the optimal cut-off value of chemotherapy-induced necrosis for EFS and OS. RESULTS: OS was 74% (95% confidence interval (CI) 67 to 79) at five years. Median chemotherapy-induced necrosis was 85% (interquartile range (IQR) 50% to 97%). In multivariate Cox model, chemotherapy-induced necrosis was significantly associated with EFS and OS (hazard ratio (HR) = 0.99 (95% CI 0.98 to 0.99); p < 0.001 and HR = 0.98 (95% CI 0.97 to 0.99); p < 0.001, respectively). Positive correlation was observed between chemotherapy-induced necrosis and five-year EFS and five-year OS (r = 0.91; p < 0.001, and r = 0.85; p < 0.001, respectively). The optimal cut-off value of chemotherapy-induced necrosis for five-year EFS and five-year OS was 85% and 72%, respectively. CONCLUSION: Chemotherapy-induced necrosis in the resected specimen showed positive correlation with EFS and OS in patients with high-grade localized osteosarcoma after MAP chemotherapy. In our analysis, optimal cut-off values of MAP chemotherapy-induced necrosis in EFS and OS were lower than the commonly used 90%, suggesting the need for re-evaluation of the optimal cut-off value through larger, international collaborative research. Cite this article: Bone Joint J 2020;102-B(6):795-803.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Tsuda Y, Tsoi K, Parry MC, et al. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. Bone Joint J. 2020. PMID: 32475245. doi:10.1302/0301-620X.102B6.BJJ-2019-1307.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。